ANI Pharmaceuticals, Inc.

Valuation Analysis

About the Company

ANI Pharmaceuticals, Inc. en bref

ANI Pharmaceuticals, Inc. (ANIP) is currently trading at 69,30 € with a market capitalization of 1,6 Md €. The trailing P/E ratio stands at 20.33x, with a forward P/E of 7.43x. The 52-week range spans from 54,58 € to 86,74 €; the current price is 20.1% below the yearly high. Year-over-year revenue growth stands at +20.5%. The net profit margin stands at 9.98%.

💰 Dividende

ANI Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent ANI Pharmaceuticals, Inc. (ANIP) au consensus : Achat Fort. L'objectif de cours moyen est de 98,26 €, soit un potentiel de +41.8% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 87,18 € à 108,10 €.

ANI Pharmaceuticals, Inc. : la thèse d'investissement en détail

ANI Pharmaceuticals, Inc. (ANIP) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 20.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 86.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 60.83%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Short interest sits at 17.84% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The forward P/E of 7.43x is meaningfully below the trailing 20.33x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 41.8% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (17.84%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy ANI Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.